Utatrectinib  (Synonyms: AZD-7451)

Utatrectinib (AZD-7451) is a potent, selective and orally active Trk inhibitor. Utatrectinib blocks TrkC activation and associated tumorigenic behaviors^[1].

Utatrectinib (100 nM, 22 h) inhibits the migration of TrkC-expressing U2SO cells^[2].
Utatrectinib (1-10 nM, 24 h) inhibits cell growth in KM12, H460 and H810 cells^[3].
Utatrectinib (5 nM, 24 h) inhibits phosphorylation of TRKA/B and downstream signaling in KM12, H460 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Utatrectinib (50 mg/kg, p.o., daily) suppresses adenoid cystic carcinoma (ACC) tumor growth in ACCX6 xenograft nu/nu mice model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

382.39

C₁₈H₁₉FN₈O

1079274-94-4

CC(C)OC1=CC(N2C=NC3=CC=C(N[C@H](C4=NC=C(F)C=N4)C)N=C32)=NN1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kozaki R, et al. Combined use of Trk inhibitor containing heterocyclic urea derivative, and other kinase inhibitor for treating cancer. WO2019049891 A1.

  [2]. Ivanov SV, et al. TrkC signaling is activated in adenoid cystic carcinoma and requires NT-3 to stimulate invasive behavior. Oncogene. 2013 Aug 8;32(32):3698-710.  [Content Brief]

  [3]. Tatematsu T, et al. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro. Mol Clin Oncol. 2014 Sep;2(5):725-730.  [Content Brief]